MSKCC/X
Jun 26, 2025, 07:39
Nancy Lee on Designing Pembrolizumab Trial for Head and Neck Cancer and FDA Approval
Memorial Sloan Kettering Cancer Center shared on X:
“The FDA has approved the immunotherapy drug pembrolizumab (Keytruda) to be given before and after surgery for patients with head and neck squamous cell cancer (HNSCC) in combination with standard therapy.
Dr. Nancy Lee, a radiologist oncologist at MSK, helped design the clinical trial showing that immunotherapy given around surgery could reduce recurrence of some head and neck cancers.
‘This is the first FDA approval in nearly two decades of a treatment for this patient group,’ she says. ‘It will be practice-changing and benefit many people.’
Learn more about Dr. Lee’s research.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 19, 2025, 21:11
Jul 19, 2025, 20:58
Jul 19, 2025, 20:26
Jul 19, 2025, 20:21